Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Stepanov

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Sensors (Basel, Switzerland)|May 1, 2019
Performance Criteria for the Identification of Inertial Sensor Error ModelsOleg Stepanov, Andrei Motorin
Sensors (Basel, Switzerland)|December 31, 2025
Recursive Batch Smoother with Multiple Linearization for One Class of Nonlinear Estimation Problems: Application for Multisensor Navigation Data FusionOleg Stepanov, Alexey Isaev, Elena Dranitsyna, et al.
Pharmaceutics|May 27, 2023
Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric PopulationAndrew Lim, Pradeep Sharma, Oleg Stepanov, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 22, 2022
A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnosticsKirill Zhudenkov, Sergey Gavrilov, Alina Sofronova, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 25, 2021
Longitudinal FEV<sub>1</sub> and Exacerbation Risk in COPD: Quantifying the Association Using Joint ModellingKirill Zhudenkov, Robert Palmér, Alexandra Jauhiainen, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 4, 2026
Stochastic Gates for Covariate Selection in Population Pharmacokinetics ModelingMarija Kekic, Oleg Stepanov, Wenjuan Wang, et al.
Clinical Pharmacology in Drug Development|September 5, 2025
Safety and Pharmacokinetics of Long-Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race EffectJing Zhang, Huixia Zhang, Yajuan Zhang, et al.
Clinical & Translational Immunology|June 14, 2024
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and <i>in vitro</i>IC<sub>50</sub> values predict SARS-CoV-2 neutralising antibody titresLindsay E Clegg, Oleg Stepanov, Sam Matthews, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2024
In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infectionChristine Tkaczyk, Michael Newton, Mun Mun Patnaik, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Sensors (Basel, Switzerland)|May 1, 2019
Performance Criteria for the Identification of Inertial Sensor Error ModelsOleg Stepanov, Andrei Motorin
Sensors (Basel, Switzerland)|December 31, 2025
Recursive Batch Smoother with Multiple Linearization for One Class of Nonlinear Estimation Problems: Application for Multisensor Navigation Data FusionOleg Stepanov, Alexey Isaev, Elena Dranitsyna, et al.
Pharmaceutics|May 27, 2023
Application of Modelling and Simulation Approaches to Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies in Pediatric PopulationAndrew Lim, Pradeep Sharma, Oleg Stepanov, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 22, 2022
A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnosticsKirill Zhudenkov, Sergey Gavrilov, Alina Sofronova, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 25, 2021
Longitudinal FEV<sub>1</sub> and Exacerbation Risk in COPD: Quantifying the Association Using Joint ModellingKirill Zhudenkov, Robert Palmér, Alexandra Jauhiainen, et al.
Antimicrobial Agents and Chemotherapy|March 27, 2024
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19Lindsay E Clegg, Oleg Stepanov, Henning Schmidt, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 4, 2026
Stochastic Gates for Covariate Selection in Population Pharmacokinetics ModelingMarija Kekic, Oleg Stepanov, Wenjuan Wang, et al.
Clinical Pharmacology in Drug Development|September 5, 2025
Safety and Pharmacokinetics of Long-Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race EffectJing Zhang, Huixia Zhang, Yajuan Zhang, et al.
Clinical & Translational Immunology|June 14, 2024
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and <i>in vitro</i>IC<sub>50</sub> values predict SARS-CoV-2 neutralising antibody titresLindsay E Clegg, Oleg Stepanov, Sam Matthews, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2024
In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infectionChristine Tkaczyk, Michael Newton, Mun Mun Patnaik, et al.
Pageof 2